Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000759070 | SCV000888155 | pathogenic | not provided | 2018-04-26 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001731305 | SCV001338379 | pathogenic | Dominant beta-thalassemia | 2023-07-27 | criteria provided, single submitter | clinical testing | Variant summary: HBB c.344T>C (p.Leu115Pro) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251222 control chromosomes (gnomAD). c.344T>C (aka. Hb Durham-N.C. or Hb Brescia) has been reported in the literature in multiple individuals affected with Dominant Beta Thalassemia (e.g. Curuk_1994, deCastro_1994, Rund_1997, Park_2002, Ropero_2012), and in many of these cases inclusion body formation was also noted. These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 8980256, 8111050, 8037185, 12144056, 21845419). Three other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and both of them classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Mayo Clinic Laboratories, |
RCV000759070 | SCV001714963 | pathogenic | not provided | 2021-03-23 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000016775 | SCV000037045 | pathogenic | Beta thalassemia intermedia | 2001-02-01 | no assertion criteria provided | literature only | |
OMIM | RCV000016776 | SCV000037046 | other | HEMOGLOBIN BRESCIA | 2017-12-12 | no assertion criteria provided | literature only | |
OMIM | RCV000016777 | SCV000037047 | other | HEMOGLOBIN DURHAM-N.C. | 2017-12-12 | no assertion criteria provided | literature only | |
Natera, |
RCV001826469 | SCV002089187 | pathogenic | beta Thalassemia | 2017-09-15 | no assertion criteria provided | clinical testing |